HRT Financial’s Quest Diagnostics DGX Stock Holding History

HRT Financial’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.11M	Buy	+41,400	New	+$8.04M	0.02%	715

Other funds holding DGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

HRT Financial's DGX Position: Q2 2025 in Review

HRT Financial sold out of Quest Diagnostics (DGX) in Q2 2025, closing a stake of 6,782 shares — an estimated $1.15M sold.

HRT Financial first reported a position in DGX in Q4 2017 and held it in 9 quarters. The position peaked at $27.2M in Q3 2021. 990 funds tracked by Wall St. Rank hold DGX as of Q2 2025.

HRT Financial reported no remaining Quest Diagnostics position as of Q2 2025 after selling out during the quarter.
HRT Financial sold 6,782 Quest Diagnostics shares in Q2 2025, an estimated $1.15M.
HRT Financial first reported a position in Quest Diagnostics in Q4 2017 and held it in 9 quarters.
HRT Financial's Quest Diagnostics position peaked at $27.2M in Q3 2021.
990 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.